MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX): $7.57

0.00 (0.00%)

POWR Rating

Component Grades













MGTX Stock Price Chart Interactive Chart >

Price chart for MGTX

MGTX Price/Volume Stats

Current price $7.57 52-week high $24.89
Prev. close $7.57 52-week low $6.59
Day low $7.33 Volume 144,200
Day high $7.78 Avg. volume 159,301
50-day MA $8.73 Dividend yield N/A
200-day MA $14.67 Market Cap 338.46M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio

MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.

MGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream

Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and Commercial Milestones Related to botaretigene sparoparvovec (AAV-RPGR), as well as for AAV-CNGB3 and AAV-CNGA3 LONDON and NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinic

Yahoo | January 27, 2022

Recent 5.8% pullback isn't enough to hurt long-term MeiraGTx Holdings (NASDAQ:MGTX) shareholders, they're still up 106% over 3 years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Yahoo | January 7, 2022

MeiraGTx (NASDAQ:MGTX) Sees Large Volume Increase

Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []

Dakota Financial News | December 21, 2021

Meiragtx Holdings (MGTX) Received its Third Buy in a Row

After Evercore ISI and Piper Sandler gave Meiragtx Holdings (NASDAQ: MGTX) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Meiragtx Holdings today and set a price target of $55.00. The company's shares closed last Thursday at $19.90. According to, Livshits is a top 100 analyst with an average return of 51.7% and a 51.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Crispr Therapeutics AG.

Howard Kim on TipRanks | December 16, 2021

A Biotech Unveils Its New Gene Control Technology

MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.

Yahoo | December 16, 2021

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo -4.78%
3-mo -46.46%
6-mo -65.20%
1-year -52.92%
3-year -74.46%
5-year N/A
YTD -68.11%
2021 56.80%
2020 -24.38%
2019 107.68%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4219 seconds.